Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,468

Transhumanists aim to do just that: to transcend the limits of the human body through the use of technology. Swiss photographer Matthieu Gafsou’s new book, H+ (Kehrer Verlag), documents Transhumanism through portraiture, still lifes and documentary photographs of Tranhumanist people, facilities, tools and technology. In photographing surgical procedures, laboratories, conferences and the like, Gafsou employed a hard flash to add a “clinical aspect” to his pictures. “This was important to me because I think [Transhumanism] is quite cold and [it] is about, not necessarily killing death but working on living longer,” he tells PDN. “But we are forgetting the body, we are forgetting the flesh, we are forgetting desire.”

In “H+,” Gafsou uses the visual language of science and technology to explore Transhumanism, the belief that the human body needs to be enhanced, perhaps even overcome.

Read more

Researchers have figured out details about how some specific type of cancers become drug-resistant.

Researchers at the Rockefeller University have clarified the mechanism by which certain types of breast cancer become immune to specific drugs designed to eliminate them. More specifically, they figured out how the loss of the protein 53BP1 due to BRCA1 mutation allows cancers to become insensitive to PARP inhibitors [1].

Study summary

Read more

You may recognize the anglerfish from its dramatic appearance in the hit animated film Finding Nemo, as it was very nearly the demise of clownfish Marlin and blue-tang fish Dory. It lives most of its life in total darkness more than 1,000 meters below the ocean surface. Female anglerfish sport a glowing lure on top of their foreheads, basically a pole with a light bulb on its end, where bioluminescent bacteria live. The light-emitting lure attracts both prey and potential mates to the fish.

Despite its recent fame, little is known about anglerfish and their symbiotic relationship with these brilliant , because the fish are difficult to acquire and study.

For the first time, scientists have sequenced and analyzed the genomes of bacteria that live in anglerfish bulbs. The bacteria were taken from fish specimens collected in the Gulf of Mexico.

Read more

A common concern in the community is that the FDA, the EMA, and other bodies, such as WHO, do not classify aging as a disease and that this poses a problem for developing therapies that target aging. However, this is not really as serious an issue as some people would suggest; today, we will have a look at why that is.

Why this will not stop progress

Aging is a variety of distinct processes, damages, and errors; therefore, simply treating aging in clinical terms is not a viable endpoint. For a clinical trial to be conducted, it requires a verifiable indication, and aging is too general for the FDA and EMA to classify it as a disease.

Read more

Cancer and rodent studies were on the crew’s timeline today to help doctors and scientists improve the health of humans in space and on Earth. The crew also conducted an emergency drill aboard the International Space Station.

Flight Engineer Serena Auñón-Chancellor examined endothelial cells through a microscope for the AngieX Cancer Therapy study. The new cancer research seeks to test a safer, more effective treatment that targets tumor cells and blood vessels. Commander Drew Feustel partnered with astronaut Alexander Gerst and checked on mice being observed for the Rodent Research-7 (RR-7) experiment. RR-7 is exploring how microgravity impacts microbes living inside organisms.

Astronaut Ricky Arnold and Gerst collected and stowed their blood samples for a pair of ongoing human research studies. Arnold went on to work a series of student investigations dubbed NanoRacks Module-9 exploring a variety of topics including botany, biology and physics.

Read more

We brought the leading experts in aging research and biotech investment together for an action-packed day of science. See what happened at this exciting event and check out our first event video now.

On July 12th, we hosted our first conference, Ending Age-Related Diseases: Investment Prospects & Advances in Research, at the Frederick P. Rose Auditorium, which is part of the Cooper Union campus in New York City. We are delighted to announce that the conference was a huge success with 160 attendees, a wide variety of speakers from both research and business, and some great discussion panels.

The goal of this conference was to promote multidisciplinary collaboration in order to foster the development of next-generation drugs and therapies that directly target the processes of aging and thus have the potential to prevent and cure age-related diseases.

For those of you who could not join us there, we have recorded the talks and panels from the conference, and we will be making them available on our website in the next few weeks once we have edited them. As a special thank you, the Lifespan Heroes, our monthly patrons, will be offered early access to these videos ahead of a public release.

Read more